Bill Hartzel has been named as Woodstock’s first Chief Commercial Officer.
Woodstock Sterile Solutions, a blow-fill-seal (BFS) contract development and manufacturing organization, announced on April 12, 2021 that it has named Bill Hartzel as its first Chief Commercial Officer.
Hartzel, who will now be responsible for the commercial activities and strategy for the company, previously served as product manager in Medication Delivery Solutions; director of Strategic Execution; regional director of Commercial Operations; and global vice-president of Business Development for Analytical, Respiratory, and Ophthalmics for Catalent, Woodstock’s predecessor, the company said in a press release.
“We are pleased to welcome a dynamic, customer-focused leader like Bill Hartzel to the Woodstock executive team,” said Paul Josephs, CEO, Woodstock, in the press release. “Bill has had an impressive career in the BFS industry and we look forward to him bringing the exceptional business and technical acumen he has demonstrated throughout his career to our leadership team to help us drive sustainable growth for the organization.”
“I am very excited about the opportunities and the potential for growth for Woodstock Sterile Solutions in the pharmaceutical and healthcare industry,” added Hartzel in the press releease. “BFS is an untapped technology and it is primed for growth and expansion—not just in the respiratory and ophthalmic space—but as a sterile delivery platform, where it can help to mitigate the risks involved with sterile manufacturing. The Woodstock business is uniquely positioned to support complex formulations seamlessly from development through commercial production. I look forward to helping Woodstock Sterile Solutions reach its full potential in this market.”
Source: Woodstock
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.